Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
The prevalence of gout is increasing, and most research on the associated burden has focused on serum urate (sUA) levels. The present study quantifies the impact of the presence of tophi and frequency of acute gout attacks on health-related quality of life (HRQOL), productivity, and healthcare resource utilization.
Patients with self-reported gout (n = 620; 338 in US and 282 across France, Germany, and UK) were contacted based on inclusion in the 2010 US and EU National Health and Wellness Surveys (Kantar Health) and the Lightspeed Research ailment panel. Respondents were categorized into mutually-exclusive groups based on number of gout flares experienced in the past 12 months (0/don’t recall, 1–2, 3, 4–5, 6+), current presence of tophi (none, 1+, or not sure), and sUA level awareness (yes, no). HRQOL (SF-12v2), healthcare provider visits in the last 6 months, and work productivity and activity impairment (WPAI) were compared across groups.
Most patients were males, mean age of 61 years, who reported experiencing at least one acute gout flare in the past 12 months, and 12.3% (n = 76) reported presence of tophi. Among the 27.7% (n = 172) of patients who were aware of their sUA levels, higher sUA was associated with more flares and tophi. Decreased HRQOL was associated with more frequent flares and presence of tophi. In multivariable models predicting outcomes based on presence of tophi and number of flares, both flares (≥4) and tophi (≥1) were associated with HRQOL decrements on physical and mental component summary scores and health utilities (all p < 0.05), after adjustment for age, gender, and time since diagnosis. Flares were also associated with greater activity impairment.
Impairments associated with gout flares and presence of tophi, across patients in the US and EU, underscore the importance of effective management of this potentially curable condition.
Supplementary Material (0)
- Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis & Rheumatism 2011, 63:3136–3141. CrossRef
- Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008, 67:960–966. CrossRef
- Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403–2406.
- Mikuls TR, Saag KG: New insights into gout epidemiology. Curr Opin Rheumatol 2006, 18:199–203. CrossRef
- Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX: A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25:1593–1617. CrossRef
- Tausche AK, Panzner I, Aust D, Wunderlich C: Disabling gout. Lancet 2010, 376:1093. CrossRef
- Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin North Am 1990, 16:539–550.
- Tausche AK, Manger B, Muller-Ladner U, Schmidt B: Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia. Z Rheumatol 2012, 71:224–230. CrossRef
- Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312–1324. CrossRef
- Perez-Ruiz F: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009,48(Suppl 2):ii9-ii14. CrossRef
- Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61–65. CrossRef
- Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Care & Research 2004, 51:321–325. CrossRef
- Murshid WR, Moss TH, Ettles DF, Cummins BH: Tophaceous gout of the spine causing spinal cord compression: Short Report. Br J Neurosurg 1994, 8:751–754. CrossRef
- Akizuki S, Matsui T: Entrapment neuropathy caused by tophaceous gout. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand 1984, 9:331–332.
- Magid SK, Gray GE, Anand A: Spinal cord compression by tophi in a patient with chronic polyarthritis: case report and literature review. Arthritis & Rheumatism 1981, 24:1431–1434. CrossRef
- Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR: The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009, 15:3–7. CrossRef
- Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356–360. CrossRef
- Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z: Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. JAMA: The Journal of the American Medical Association 2011, 306:711. CrossRef
- Saag KG, Choi H: Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006,8(Suppl 1):S2. CrossRef
- Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009, 48:582–586. CrossRef
- Singh JA, Reddy SG, Kundukulam J: Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011, 23:192–202.
- Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, Tsevat J: The disutility of chronic gout. Qual Life Res 2008, 17:815–822. CrossRef
- Khanna PP, Perez-Ruiz F, Maranian P, Khanna D: Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011, 50:740–745. CrossRef
- Singh JA, Strand V: Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008, 67:1310–1316. CrossRef
- DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W: Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010, 13:709–718. CrossRef
- Bolge SC, Doan JF, Kannan H, Baran RW: Association of insomnia with quality of life, work productivity, and activity impairment. Quality of life Research 2009, 18:415–422. CrossRef
- Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12 Health Survey. Quality Metric, Lincoln, RI; 2002.
- Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Heal Econ 2002, 21:271–292. CrossRef
- Hays RD, Morales LS: The RAND-36 measure of health-related quality of life. Ann Med 2001, 33:350–357. CrossRef
- Walters SJ, Brazier JE: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14:1523–1532. CrossRef
- Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4:353–365. CrossRef
- Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical care 2003, 41:582.
- Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M: Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther 2011.
- Roddy E, Zhang W, Doherty M: Is gout associated with reduced quality of life? A case–control study. Rheumatology (Oxford) 2007, 46:1441–1444. CrossRef
- Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, et al.: Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36:1041–1048. CrossRef
- Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N: The economic burden of gout on an employed population. Curr Med Res Opin 2006, 22:1381–1389. CrossRef
- Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, van Zanten SV: Gout in the elderly–a population health study. J Rheumatol 2009, 36:822–830. CrossRef
- Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, Kavanaugh A, Hirsch JD: Health care utilization in patients with gout. Semin Arthritis Rheum 2011, 40:501–511. CrossRef
- Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009, 36:1032–1040. CrossRef
- Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N: The impact of gout on work absence and productivity. Value Health 2007, 10:231–237. CrossRef
- Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA: Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011, 14:10–15. CrossRef
- Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093–1103. CrossRef
- Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin N Am 1990, 16:539.
- McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC: Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 2011, 38:135–141. CrossRef
About this Article
- Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Health and Quality of Life Outcomes
- Online Date
- September 2012
- Online ISSN
- BioMed Central
- Additional Links
- Quality of life
- Refractory chronic gout
- Author Affiliations
- 1. University of Michigan, Kragujevac, Michigan, USA
- 2. Western General Hospital, Edinburgh, UK
- 3. Hospital Lariboisiere, Paris, France
- 4. University Clinic, Dresden, Germany
- 5. Novartis Pharmaceuticals, Inc, East Hanover, NJ, USA
- 6. Kantar Health, New York, NY, USA
- 7. Kantar Health, Princeton, NJ, USA